IN2014DN06127A - - Google Patents

Info

Publication number
IN2014DN06127A
IN2014DN06127A IN6127DEN2014A IN2014DN06127A IN 2014DN06127 A IN2014DN06127 A IN 2014DN06127A IN 6127DEN2014 A IN6127DEN2014 A IN 6127DEN2014A IN 2014DN06127 A IN2014DN06127 A IN 2014DN06127A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Colin F Spraggs
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of IN2014DN06127A publication Critical patent/IN2014DN06127A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN6127DEN2014 2012-01-31 2014-07-21 IN2014DN06127A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592893P 2012-01-31 2012-01-31
US201261654733P 2012-06-01 2012-06-01
PCT/EP2013/051865 WO2013113796A1 (fr) 2012-01-31 2013-01-31 Méthode de traitement du cancer

Publications (1)

Publication Number Publication Date
IN2014DN06127A true IN2014DN06127A (fr) 2015-08-14

Family

ID=47714037

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6127DEN2014 IN2014DN06127A (fr) 2012-01-31 2014-07-21

Country Status (11)

Country Link
US (1) US20150023953A1 (fr)
EP (2) EP3045543A3 (fr)
JP (1) JP2015506955A (fr)
KR (1) KR20140117644A (fr)
CN (1) CN104204226A (fr)
AU (1) AU2013214254B2 (fr)
BR (1) BR112014019034A8 (fr)
CA (1) CA2863287A1 (fr)
IN (1) IN2014DN06127A (fr)
RU (1) RU2014135224A (fr)
WO (1) WO2013113796A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504743A (zh) * 2017-09-13 2019-03-22 复旦大学附属华山医院 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒
CN115427456A (zh) * 2020-01-29 2022-12-02 得克萨斯州大学系统董事会 基于喹唑啉的酪氨酸激酶抑制剂在具有nrg1融合的癌症的治疗中的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997040462A2 (fr) 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Formes polymorphes en correlation au niveau de phenotypes multiples
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
BR0111947A (pt) 2000-06-30 2003-05-06 Glaxo Group Ltd Composto, composição farmacêutica, método para o tratamento de um distúrbio em um mamìfero, uso de um composto e processo para preparar, um composto
WO2007095038A2 (fr) * 2006-02-09 2007-08-23 Novartis Ag Mutations et polymorphismes du gène erbb2
AU2008205457A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
US20100104583A1 (en) * 2007-01-18 2010-04-29 University Of Southern California Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy
EP1980626A1 (fr) * 2007-04-13 2008-10-15 Het Nederlands Kanker Instituut Implication de kinase de lipide, et passage de transduction du signal comportant cette kinase de lipide, en résistance à la thérapie de ciblage HER2
WO2008128233A1 (fr) * 2007-04-15 2008-10-23 University Of Chicago Procédés et compositions concernant le gène vegfr-2 (récepteur de domaine kinase, kdr)
BR112012003653A2 (pt) * 2009-08-21 2016-03-22 Smithkline Beecham Cork Ltd "método de tratar o câncer."
WO2011060380A1 (fr) * 2009-11-14 2011-05-19 The Regents Of The University Of California L'état de mutation de pik3ca et l'expression de sash1 prédisent la synergie entre le lapatinib et un inhibiteur d'akt dans le cancer du sein her2 positif

Also Published As

Publication number Publication date
RU2014135224A (ru) 2016-03-27
JP2015506955A (ja) 2015-03-05
WO2013113796A1 (fr) 2013-08-08
AU2013214254B2 (en) 2016-04-21
BR112014019034A2 (fr) 2017-06-20
US20150023953A1 (en) 2015-01-22
KR20140117644A (ko) 2014-10-07
EP2809805A1 (fr) 2014-12-10
CN104204226A (zh) 2014-12-10
AU2013214254A1 (en) 2014-08-14
CA2863287A1 (fr) 2013-08-08
BR112014019034A8 (pt) 2017-07-11
EP3045543A2 (fr) 2016-07-20
EP3045543A3 (fr) 2016-10-12

Similar Documents

Publication Publication Date Title
BR112014025798A2 (fr)
BR112014017635A2 (fr)
BR112014017690A2 (fr)
BR112014020801A2 (fr)
BR112014017625A2 (fr)
BR112014017659A2 (fr)
BR112014017592A2 (fr)
BR112014017607A2 (fr)
AR092201A1 (fr)
BR112014017644A2 (fr)
BR112014017634A2 (fr)
BR112014017588A2 (fr)
BR112014017647A2 (fr)
BR112014013184A8 (fr)
BR112014017627A2 (fr)
BR112014017623A2 (fr)
BR112014017630A2 (fr)
BR112014023107A2 (fr)
BR112014017621A2 (fr)
BR112014017631A2 (fr)
BR112014017622A2 (fr)
BR112014017671A2 (fr)
BR112014017589A2 (fr)
BR112014017600A2 (fr)
BR112014017636A2 (fr)